Despite JAK ‘anxiety,’ ICER experts overwhelmingly back Incyte’s ruxolitinib cream in atopic dermatitisnews2021-07-26T14:16:26+00:00July 26th, 2021|Fierce Pharma|
Bristol Myers, yielding to FDA pressure, pulls Opdivo in post-Nexavar liver cancernews2021-07-26T09:47:28+00:00July 26th, 2021|Fierce Pharma|
AstraZeneca’s newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog saysnews2021-07-23T18:46:36+00:00July 23rd, 2021|Fierce Pharma|
CDMO Recipharm continues its rapid expansion with a second fill-finish facility, this time in Indianews2021-07-23T15:44:23+00:00July 23rd, 2021|Fierce Pharma|
Lumen plots site at nearby Seattle bakery as it ramps up production of algae-based biologicsnews2021-07-23T15:37:08+00:00July 23rd, 2021|Fierce Pharma|
Meet the new GSK consumer health boss after spinoff, same as the old boss despite Elliott’s threat for changenews2021-07-23T14:24:03+00:00July 23rd, 2021|Fierce Pharma|
Takeda lays out $126M to tap robotics, virtual reality and more at California production sitenews2021-07-23T13:25:54+00:00July 23rd, 2021|Fierce Pharma|
Pfizer-BioNTech sign on to provide 200 million more COVID-19 vaccine doses to the U.S.news2021-07-23T13:21:56+00:00July 23rd, 2021|Fierce Pharma|
Novartis on the hook for $178M after losing Tafinlar patent fight with Daiichi’s Plexxikon businessnews2021-07-23T11:13:20+00:00July 23rd, 2021|Fierce Pharma|
Fierce Pharma Asia—Junshi’s mRNA JV; Novartis’ China business; Roche’s Ronapreve COVID nod in Japannews2021-07-23T09:04:51+00:00July 23rd, 2021|Fierce Pharma|
